Effect of Dapagliflozin on Clinical Outcomes in Patients with Chronic Kidney Disease, With and Without Cardiovascular Disease.

@article{McMurray2020EffectOD,
  title={Effect of Dapagliflozin on Clinical Outcomes in Patients with Chronic Kidney Disease, With and Without Cardiovascular Disease.},
  author={John J. V. McMurray and David C. Wheeler and Bergur V. Stef{\'a}nsson and Niels Jongs and Douwe Postmus and Ricardo Correa-Rotter and Glenn M. Chertow and Tom Greene and Claes Held and Fan Fan Hou and Johannes F E Mann and Peter Rossing and Carl David Sj{\"o}str{\"o}m and Robert D. Toto and Anna Maria Langkilde and Hiddo J Lambers Heerspink},
  journal={Circulation},
  year={2020}
}
Background: Dapagliflozin reduces the risk of end-stage renal disease in patients with chronic kidney disease. We examined the relative risk of cardiovascular and kidney events in these patients and the effect of dapagliflozin on either type of event, taking account of history of cardiovascular disease. Methods: In the DAPA-CKD trial (Dapagliflozin And Prevention of Adverse Outcomes in Chronic Kidney Disease), 4304 participants with chronic kidney disease were randomized to dapagliflozin 10 mg… 

Figures and Tables from this paper

Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure.
Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
TLDR
Among patients with stage 4 CKD and albuminuria, dapagliflozin's benefits were consistent with those observed in the DAPA-CKD trial overall, with no evidence of increased risks.
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease: results of the DAPA-CKD study
TLDR
Dapagliflozin demonstrated the ability, in comparison with placebo, to reduce the primary composite point and a number of secondary composite points in patients with both diabetic and non-diabetic CKD.
SGLT2 inhibitors as cardio-renal protective agents.
Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis
TLDR
For stage 3/4 CKD, SGLT2 inhibitors significantly decreased the risk of primary cardiovascular outcomes, and these benefits were consistent throughout the spectrum of different kidney functions, even in stage 4 CKD.
Use of SGLT-2 Inhibitors in Patients with Chronic Kidney Disease.
  • A. Mottl
  • Medicine
    The Journal of family practice
  • 2021
TLDR
Sodium-glucose cotransporter-2 inhibitors are first-line agents for treatment of patients with type 2 diabetes mellitus and CKD or a history of atherosclerotic CV disease and dapagliflozin has demonstrated equivalent efficacy for reducing kidney events irrespective of diabetes status.
A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease
In recent years, inhibitors of the sodium-glucose co-transporter 2 (SGLT2 inhibitors) have been shown to have significant protective effects on the kidney and the cardiovascular system in patients
Risk of outcomes in a Spanish population with chronic kidney disease
TLDR
The presence of HF among CKD patients markedly increases the risk of outcomes and patients have a high risk of HF, which could be partially related to insufficient treatment.
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the DARE‐19 study
TLDR
Dapagliflozin, a sodium‐glucose cotransporter‐2 inhibitor, has shown significant cardio‐ and renoprotective benefits in patients with type 2 diabetes, heart failure and chronic kidney disease, and may provide similar organ protection in high‐risk patients with COVID‐19.
...
...

References

SHOWING 1-10 OF 29 REFERENCES
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
TLDR
In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE than placebo but did result in anLower rate of cardiovascular death or hospitalization for heart failure, a finding that reflects a lower rates of hospitalizationFor heart failure.
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
TLDR
The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined.
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
  • H. Heerspink, B. Stefánsson, Pham Van Bui
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2020
TLDR
DAPA-CKD will determine whether the SGLT2 inhibitor dapagliflozin, added to guideline-recommended therapies, safely reduces the rate of renal and cardiovascular events in patients across multiple CKD stages with and without diabetes.
Dapagliflozin in Patients with Chronic Kidney Disease.
TLDR
Among patients with chronic kidney disease, regardless of the presence or absence of diabetes, the risk of a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease or death from renal or cardiovascular causes was significantly lower with dapagliflozin than with placebo.
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
  • D. Wheeler, B. Stefánsson, H. Heerspink
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2020
TLDR
The DAPA-CKD trial will examine the efficacy and safety of dapagliflozin in participants with CKD Stages 2–4 and increased albuminuria, with and without type 2 diabetes.
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
TLDR
Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than amongThose who received placebo, regardless of the presence or absence of diabetes.
Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease
TLDR
Although current treatment of patients with CKD includes management of traditional and nontraditional risk factors, the value of modifying some nontraditionally risk factors remains unclear.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
TLDR
Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care.
...
...